Shalabh Gupta

Shalabh Gupta is a physician by training who transitioned his career towards entrepreneurship in the healthcare and biotechnology sectors, focusing on bringing new technologies to the market to benefit patients, physicians, and society.

He founded Unicycive in 2016, a company dedicated to developing innovative treatments for kidney diseases, which went public in July 2021. Prior to Unicycive, Shalabh founded Biocycive, which was acquired by Sorrento Therapeutics, and Globavir, focusing on infectious diseases diagnostics and treatments.

Before his entrepreneurial ventures, Shalabh worked at Genentech in commercial strategy, with experience in in-line and pipeline drugs. He also had a decade-long career as a practicing physician and served as a medical director for biotech companies.

In addition to his roles in the industry, Shalabh has a strong educational background, having studied Medicine at New York University School of Medicine and Public Administration at NYU's Robert F. Wagner Graduate School of Public Service.

He is involved in various organizations, having served on advisory boards, as a founder and CEO of multiple companies, and as a fellow at the Startup Leadership Program. Shalabh's wide-ranging experience encompasses equity research on Wall Street and strategic roles at prominent healthcare organizations.